A newly unredacted antitrust lawsuit against individual defendants and 20 corporate makers of generic drugs reveals details of how the pharmaceutical companies allegedly conspired to fix prices on more than 100 medications.
The companies describe their practices using such terms as “fair share” or “playing nice in the sandbox.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]